List of Excipients in Branded Drug WIXELA INHUB

Generic Drugs Containing WIXELA INHUB

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	fluticasone propionate and salmeterol	0378-9320	LACTOSE MONOHYDRATE
Bryant Ranch Prepack	fluticasone propionate and salmeterol	63629-4989	LACTOSE MONOHYDRATE
REMEDYREPACK INC	fluticasone propionate and salmeterol	70518-2501	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in WIXELA INHUB?

# Of NDCs	Excipient
3	LACTOSE MONOHYDRATE

Last updated: September 3, 2026

Wixela Inhub is a dry-powder inhaler containing fluticasone propionate and salmeterol xinafoate. Its excipient strategy is built around lactose monohydrate as a carrier, with device and powder-engineering controls that support dose uniformity, aerosol dispersion, moisture management, and generic substitution. The main commercial opportunities are lower-cost manufacturing, regional supply, authorized-generic competition, device differentiation, and lifecycle extensions that improve adherence without changing the active ingredients.

Wixela Inhub Excipient Strategy and Commercial Opportunities

What is Wixela Inhub and how is it positioned commercially?

Wixela Inhub is Viatris’ dry-powder inhaled combination of fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist. It is approved for twice-daily maintenance treatment of asthma and chronic obstructive pulmonary disease in three strengths:

Wixela Inhub strength	Fluticasone propionate per dose	Salmeterol per dose
100/50 mcg	100 mcg	50 mcg
250/50 mcg	250 mcg	50 mcg
500/50 mcg	500 mcg	50 mcg

The product is therapeutically equivalent to Advair Diskus, the reference inhaler marketed by GlaxoSmithKline. The FDA approved Wixela Inhub in January 2019 as the first generic equivalent to Advair Diskus in the United States. The approval created a lower-price alternative in a high-volume respiratory market while preserving the fluticasone/salmeterol combination and dry-powder delivery model.[1]

Wixela Inhub uses a breath-actuated device. The patient opens the mouthpiece, inhales through the device, and receives a metered dose. The device includes a dose counter and audible and visual feedback intended to confirm dose preparation and inhalation.[2]

The commercial value is not determined by the excipient alone. It depends on the interaction among:

• micronized active pharmaceutical ingredients;
• lactose carrier particles;
• powder blending and deagglomeration;
• inhaler resistance and airflow design;
• moisture protection;
• dose metering;
• patient handling;
• device manufacturing cost; and
• regulatory evidence for product equivalence.

What excipients are used in Wixela Inhub?

Wixela Inhub uses lactose monohydrate as the principal inactive ingredient. The lactose carrier supports the handling and dispersion of very low-dose micronized drug particles in the inhaler.[2]

The active ingredients are fluticasone propionate and salmeterol xinafoate. The drug substances are present in small quantities relative to the lactose carrier. A dry-powder inhaler therefore requires a controlled carrier system to produce reproducible emitted and fine-particle doses.

Excipient composition and functional role

Component	Function in the formulation	Commercial relevance
Lactose monohydrate	Carrier and bulking agent for micronized drug particles	Main excipient cost and supply-chain variable
Fluticasone propionate	Inhaled corticosteroid	Requires uniform low-dose distribution
Salmeterol xinafoate	Long-acting bronchodilator	Requires controlled blending with the corticosteroid and carrier
Device components	Metering, deagglomeration, airflow, dose protection, dose counting	Major source of product differentiation

Lactose is not an inert commodity input in this context. Particle-size distribution, morphology, surface energy, moisture content, crystallinity, and supplier consistency can affect drug adhesion, powder flow, emitted dose, and fine-particle fraction.

The label identifies lactose as an ingredient and warns that Wixela Inhub contains a small amount of lactose, which may contain milk proteins. Patients with severe milk-protein allergy are therefore a specific safety consideration.[2]

How does lactose function in the Wixela Inhub powder?

Lactose acts as a carrier for micronized fluticasone propionate and salmeterol xinafoate. The drug particles are substantially smaller than the carrier particles. During inhalation, airflow and device geometry separate a portion of the active particles from the lactose surface, allowing the drug to reach the respiratory tract.

The carrier must balance competing properties:

1. It must support uniform blending at low drug concentrations.
2. It must permit adequate drug detachment during inhalation.
3. It must resist excessive agglomeration during storage.
4. It must maintain acceptable flow through the metering system.
5. It must remain stable across humidity and temperature conditions.

A carrier that binds the drug too strongly can reduce respirable delivery. A carrier that binds too weakly can increase segregation, dose variability, and manufacturing losses.

Key excipient control attributes

Commercial development should monitor:

• lactose particle-size distribution;
• fine lactose fraction;
• surface roughness;
• residual moisture;
• polymorphic form;
• bulk and tapped density;
• electrostatic behavior;
• drug-to-carrier adhesion;
• blend uniformity;
• emitted dose;
• fine-particle dose;
• mass median aerodynamic diameter; and
• delivered-dose stability after device actuation.

These attributes are closely connected. Changing lactose supplier, milling conditions, or humidity exposure can change aerosol performance even when the nominal composition remains unchanged.

What formulation patents protect Wixela Inhub?

Wixela Inhub is a generic product approved against Advair Diskus. The key regulatory protection was established through the abbreviated new drug application pathway rather than through a new chemical-entity exclusivity period.

Publicly available product information identifies the approved formulation as a fluticasone propionate and salmeterol xinafoate dry powder delivered through the Inhub device. The commercially important intellectual-property layers are likely to include:

• inhaler architecture;
• dose-metering mechanisms;
• airflow and deagglomeration structures;
• dose-counter integration;
• powder-loading and packaging processes;
• manufacturing controls for the drug-carrier blend; and
• know-how concerning device filling, sealing, and performance testing.

The exact live patent position must be assessed by jurisdiction, patent family, claim scope, terminal disclaimers, maintenance fees, and litigation history. Product-label information alone does not establish that a specific patent remains enforceable or blocks a competing inhaler.

For commercial diligence, the relevant patent search should distinguish among:

IP category	Potential commercial effect
Device patents	May block a substantially similar inhaler architecture
Formulation patents	May restrict specific carrier, particle, or excipient systems
Manufacturing patents	May affect powder blending, filling, or dose-metering processes
Method-of-use patents	May cover particular patient populations or dosing regimens
Trade secrets	May protect process windows that are difficult to reproduce from public documents

What is the Orange Book status of Wixela Inhub?

Wixela Inhub was approved through an ANDA as a generic equivalent to Advair Diskus. FDA-approved generic drug products are listed in the Orange Book with therapeutic-equivalence information, but the patent-certification and listing analysis is tied primarily to the reference listed drug and the ANDA pathway.[3]

The principal regulatory milestones were:

Milestone	Date or status
Advair Diskus reference product	GlaxoSmithKline
Wixela Inhub FDA approval	January 2019
Product pathway	ANDA
Dosage form	Inhalation powder
Strengths	100/50, 250/50, 500/50 mcg
Therapeutic-equivalence objective	Equivalent to Advair Diskus
New chemical entity exclusivity	Not applicable to Wixela Inhub
Biosimilar pathway	Not applicable

Wixela Inhub is not a biologic and has no biosimilar exposure. Competitive risk comes from generic inhalers, authorized generics, branded alternatives, and other inhaled corticosteroid/long-acting bronchodilator combinations.

When does Wixela Inhub lose exclusivity?

Wixela Inhub did not receive new chemical entity exclusivity because it is a generic version of an established combination product. Its market position depends on the absence of enforceable blocking patents, regulatory approval of competing products, payer placement, manufacturing economics, and the strength of the Inhub device and formulation platform.

The relevant commercial distinction is between regulatory exclusivity and practical market protection:

• Regulatory exclusivity: no separate NCE period applies to Wixela Inhub.
• Patent protection: may attach to device, formulation, process, or method claims.
• Market protection: depends on substitution, contracts, formulary access, and manufacturing scale.
• Device differentiation: may reduce direct substitution even when the active ingredients are the same.

A generic competitor can face a higher development burden than an oral solid despite using the same active ingredients. Inhalation products require comparative aerodynamic performance, device testing, dose-content uniformity, stability, and human-factor evidence. These requirements can delay entry without creating formal exclusivity.

What Paragraph IV challenges and litigation affect Wixela Inhub?

Wixela Inhub entered the market as an ANDA product after patent and regulatory disputes surrounding Advair Diskus had already shaped the generic pathway. The product’s approval did not create a new patent estate equivalent to that of a novel branded inhaler.

There is no broadly established, product-specific Paragraph IV litigation record that can be reliably attributed to Wixela Inhub without a current docket and Orange Book review. Paragraph IV risk is more relevant to future competitors challenging patents covering:

• the Inhub device;
• competing fluticasone/salmeterol delivery systems;
• inhaler dose counters;
• powder formulation controls; and
• process claims.

For investors and licensors, the central question is whether a proposed competitor can avoid the relevant device claims while achieving equivalent aerosol performance. A non-infringing device with a different metering or airflow architecture may have greater strategic value than a me-too formulation using the same inhaler concept.

What manufacturing and excipient barriers affect generic entry?

The highest barriers are usually technical rather than raw-material related.

Powder-processing barriers

Fluticasone propionate and salmeterol xinafoate must be blended uniformly with lactose at low drug concentrations. Small changes in mixing energy, order of addition, environmental humidity, or equipment geometry can affect content uniformity and aerosol performance.

Device-filling barriers

The inhaler must receive reproducible powder quantities across multiple doses. Filling variation can alter both nominal dose and delivered dose. The manufacturer must control powder flow, hopper behavior, electrostatic charging, and container closure.

Moisture barriers

Dry powders can absorb moisture during processing and storage. Moisture can increase agglomeration, alter drug-carrier adhesion, and reduce dispersibility. Packaging and device sealing are therefore part of the product strategy.

Analytical barriers

A commercially viable competitor needs validated methods for:

• delivered-dose uniformity;
• aerodynamic particle-size distribution;
• fine-particle dose;
• assay and impurities;
• blend uniformity;
• device performance;
• leachables and extractables; and
• in-use stability.

These controls increase the cost of entry and create opportunities for specialist contract development and manufacturing organizations.

What commercial opportunities exist for Wixela Inhub excipients?

Low-cost lactose sourcing

Lactose is available from multiple global suppliers, but inhalation-grade material requires tighter controls than ordinary pharmaceutical lactose. A dual-source strategy can reduce supply risk, provided equivalence studies support supplier changes.

Commercial opportunities include:

• qualified inhalation-grade lactose supply;
• controlled particle-size fractions;
• custom surface-treated lactose;
• low-moisture grades;
• regional manufacturing and warehousing; and
• supplier qualification services.

Excipient engineering

A carrier engineered for improved drug detachment could increase fine-particle delivery or reduce variability. Potential approaches include controlled particle morphology, optimized fines content, or surface modification. Any change must preserve regulatory comparability and avoid creating new safety or stability concerns.

Device-compatible formulation services

The most valuable service opportunity is formulation-device co-development. A powder that performs well in one inhaler may fail in another because inhalation resistance, airflow path, and deagglomeration forces differ.

Specialist providers can offer:

• design-of-experiments studies;
• lactose and API co-processing;
• inhaler filling development;
• aerosol performance optimization;
• humidity-stress testing; and
• scale-up support.

Regional supply and licensing

Wixela Inhub creates opportunities for regional commercialization where Advair-type products remain expensive or access is limited. Licensing models may include:

• territory-specific distribution;
• local device assembly;
• contract filling;
• supply of inhalation-grade lactose;
• technology transfer for powder blending; and
• co-development of a non-infringing inhaler.

No major public licensing transaction is required to establish these opportunities. The commercial value depends on whether the proposed partner controls device intellectual property, manufacturing capacity, or regulatory access in the target market.

How does Wixela Inhub compare with Advair Diskus?

Attribute	Wixela Inhub	Advair Diskus
Active ingredients	Fluticasone propionate and salmeterol xinafoate	Fluticasone propionate and salmeterol xinafoate
Product type	Generic dry-powder inhaler	Branded reference product
FDA pathway	ANDA	NDA
Device	Inhub	Diskus
Carrier strategy	Lactose-based dry powder	Lactose-based dry powder
Primary commercial position	Lower-cost alternative	Originator brand
Main differentiation	Price, device handling, formulary access	Brand history, prescriber familiarity, established device
Biosimilar risk	None	None
Generic substitution risk	Direct generic competition	Generic and therapeutic competition

The products share active ingredients but do not use identical devices. Device handling, preparation steps, airflow resistance, dose feedback, and patient familiarity can affect real-world substitution.

What generic launch risks exist for Wixela Inhub?

The principal risks are:

1. A competing inhaler may obtain therapeutic-equivalence status and gain preferred formulary placement.
2. A lower-cost manufacturer may reduce reimbursement or contract pricing.
3. Device-specific patents may restrict close copies.
4. Lactose or API supply disruptions may affect production.
5. Patient-training requirements may slow switching from Diskus or Inhub.
6. Regulatory review may identify differences in aerosol performance or device usability.
7. Combination-inhaler competitors may shift treatment toward newer long-acting therapies.

Wixela Inhub’s strongest defense is a combination of reliable supply, competitive net pricing, robust device performance, and payer access. Excipient optimization can improve margin and resilience, but it is unlikely to create durable commercial protection by itself unless paired with defensible process or device intellectual property.

Key Takeaways

• Wixela Inhub contains fluticasone propionate and salmeterol xinafoate in a lactose-based dry-powder formulation.
• Lactose is the central excipient and functions as a carrier for micronized drug particles.
• Particle size, surface properties, moisture, blending, and device airflow determine commercial performance.
• Wixela Inhub is an ANDA-approved generic equivalent to Advair Diskus and has no biosimilar pathway.
• Its practical protection depends more on device engineering, manufacturing know-how, supply reliability, and payer access than on new-drug exclusivity.
• The strongest excipient opportunities involve inhalation-grade lactose, carrier engineering, dual sourcing, and formulation-device development services.
• Generic-entry risk is driven by competing dry-powder inhalers, price pressure, formulary decisions, and the ability to design around device patents.
• No major public licensing transaction is necessary for a commercial opportunity, but territory-specific distribution, contract manufacture, and device technology transfer are plausible models.

FAQs About Wixela Inhub Excipient and Patent Strategy

Does Wixela Inhub contain lactose?

Yes. Wixela Inhub uses lactose monohydrate as a carrier excipient, and the lactose may contain small amounts of milk proteins.[2]

Is Wixela Inhub interchangeable with Advair Diskus?

FDA approved Wixela Inhub as a generic equivalent to Advair Diskus. Substitution practices depend on FDA therapeutic-equivalence status, state pharmacy law, payer policy, and the prescribed product.

Can a company develop a lactose-free Wixela Inhub competitor?

A lactose-free dry-powder competitor may be technically possible, but it would require a different powder-engineering strategy and comparative evidence for dose uniformity, aerosol performance, stability, and safety.

What is the most valuable excipient opportunity in fluticasone/salmeterol inhalers?

The most valuable opportunity is usually controlled inhalation-grade lactose combined with formulation-device development. Commodity lactose alone has less differentiation than a validated carrier system with reproducible aerosol performance.

Is Wixela Inhub exposed to biosimilar competition?

No. Wixela Inhub is a small-molecule combination inhaler, not a biologic. Its competitive exposure is to generic inhalers and other inhaled corticosteroid/long-acting bronchodilator products.

References

1. U.S. Food and Drug Administration. (2019). FDA approves first generic versions of Advair Diskus to treat asthma, COPD. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-versions-advair-diskus-treat-asthma-copd

2. U.S. National Library of Medicine. (2024). Wixela Inhub: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ind​​ex.cfm